INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE ENTERED INTO AN AI CO-DEVELOPMENT COLLABORATION WITH A CONTRACT VALUE UP TO TENS OF MILLIONS OF U.S. DOLLARS TO BUILD AND COMMERCIALIZE FOUNDATION MODELS FOR BIOLOGY

This announcement is made by InSilico Medicine Cayman TopCo (the "**Company**", together with its subsidiaries, the "**Group**" or "**Insilico Medicine**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that, the Company has entered into a collaboration with a frontier foundation model lab, with a contract value up to tens of millions of U.S. dollars. Under the agreement, the two companies will leverage the MMAI Gym training framework to co-develop, validate, and commercialize a series of frontier foundation models specifically engineered for biological research.

Pursuant to the terms of the collaboration, the collaboration will deeply integrate the strength of both parties to build specific foundation models for generative biology. Insilico Medicine will contribute proprietary datasets spanning multiple specialized life science tasks and execute closed-loop wet-lab experimental validations on the outputs generated by the foundation models during training. Furthermore, the parties have established a revenue-sharing framework to drive global commercialization across their respective biopharmaceutical partner networks.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, September 21, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as a non-executive director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.